Further Evidence in Favor of Non-Invasive Vasospasm Diagnosis

Non-invasive coronary vasospasm diagnosis by means of echocardiography with the administration of ergonovine can be performed safely; even without prior angiography to rule out fixed lesions.

These data are encouraging and move patients with vessel spasm but without significant lesions away from multiple angiographies and from the uncertainty of a diagnosis “by exclusion.”

This work recently published in JACC Cardiovasc Imaging sought large-scale evidence to support the clinical utility of ergonovine echocardiography for the diagnosis of coronary spasms.

The test was performed in 14,012 patients (mean age 52 years; 44.3% were women) after ruling out significant coronary arterial stenosis by functional (stress electrocardiography or single photon emission computed tomography [SPECT], n = 9,824) or anatomic testing (tomography or conventional angiography, n = 4,188).

Only 0.4% of patients had to stop the study early, and a positive result was obtained in 2144 patients (15.3%). Said positive result had variable frequencies according to the presumptive diagnosis for each patient at baseline (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], and syncope [9.9%]).


Read also: Diabetes Could Decide between Ticagrelor and Prasugrel.


There were no mortality or infarction events during the study with ergonovine.

During a median follow-up of 11.4 years (range: 7.2 to 15.8), all-cause death and cardiovascular death occurred in 494 and 143 patients, respectively.

Compared with patients with positive ergonovine test results, the functional test group and the anatomic test group did not show a significant difference in events.


Read also: How To De-Escalate Prasugrel After Acute Coronary Syndrome?


After multiple adjustments, having a positive ergonovine echocardiogram was an independent factor linked to all-cause mortality (hazard ratio [HR]: 1.879, p < 0.001) and cardiovascular death (HR: 2.903, p < 0.001).

Conclusion

Ergonovine echocardiography may be a safe diagnostic tool for coronary vasospasm, even without anatomic documentation. These results have major long-term prognosis implications, and might even replace invasive provocation testing.

Original Title: Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm.

Reference: Sang Yong Om et al. JACC Cardiovasc Imaging. 2020 Sep;13(9):1875-1887. doi: 10.1016/j.jcmg.2020.03.008.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...